MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy - Wikidata - awgldk - TriplyDB

MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy

MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy

http://www.wikidata.org/entity/Q34400398

about

Tumor suppressor p53 and its gain-of-function mutants in cancer Aberrant regulation of FBW7 in cancer.Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations.Zinc supplementation suppresses 4-nitroquinoline 1-oxide-induced rat oral carcinogenesis.Resveratrol-induced apoptosis is enhanced in low pH environments associated with cancer.Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors.Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice Systems analysis reveals a transcriptional reversal of the mesenchymal phenotype induced by SNAIL-inhibitor GN-25.Role of p53 in Cell Death and Human Cancers.Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system Targeting p53-MDM2-MDMX loop for cancer therapy.Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.Zinc and zinc-containing biomolecules in childhood brain tumors.Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas.

P2860

Q27000754-CCD3A5D1-0275-4C5A-B6D8-B8E044305002 Q33688508-DCE98D7C-9AB8-43E9-8F7B-11C4F399BCBB Q33976883-91F26594-1163-4027-B345-3ACEB54A1465 Q34684352-3E537CF5-15D0-4164-8A2D-21480DEEB931 Q34734112-892138B5-D752-42DA-8D62-02F5251B0CEB Q35256597-FB1AA744-FC0A-4521-9EE9-79C4A8348958 Q35640255-762F78CA-DD4D-4C3B-9492-1692ED66147C Q36675242-1C47CAC1-AB46-41A8-B9F3-8786CABDDBD8 Q37360050-988BBF2E-6FD1-4B7A-B1BC-1FD84998785E Q38161342-ACE54F64-9404-4482-B91F-7716AD04D9C4 Q38181445-22064A33-9548-4C6E-BF00-3AE8F48D0501 Q38247168-EA6E5E89-3C7D-43C9-878B-9161FC849816 Q38722567-04739E26-CF74-45DB-B075-19687F8C454A Q38738390-55DC25C5-442E-4DE7-A760-5E896852C5C0 Q38957110-BBCFF99A-1CF9-4C03-B488-761B85781619 Q41470933-86A8D1C7-D414-447E-964D-D17724521BD5

P2860

MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy

http://www.wikidata.org/entity/Q34400398

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy

@ast

MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy

@en

MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy

@nl

type

label

MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy

@ast

MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy

@en

MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy

@nl

prefLabel

MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy

@ast

MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy

@en

MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy

@nl

P1433

Q34400398-A0B7F12E-3247-4C80-9996-15EAE6E7D3D6

P1476

Q34400398-76926C8F-1C7A-4581-8EFF-6D99B876D081

P2093

Q34400398-1C1130E8-1811-4297-88A4-61942CCBFCA1

Q34400398-298EB6F9-AB8E-4094-82F8-B8E94D02E3DF

Q34400398-3DCA7015-517A-421F-984A-49C69D45D959

Q34400398-74337765-52B7-4971-8276-C255A62F7C8C

Q34400398-93D088C9-626C-4883-A135-52A070A5C3AF

Q34400398-9F6B964B-3273-48C2-8E29-EDEB9E8F1BE8

Q34400398-DA7586AB-D604-4844-B3A1-7AE7452CF456

Q34400398-E5D8E051-D972-478A-93A4-FF89D3B218DD

Q34400398-EB14E4D9-07F3-422E-B096-1088FE039CBE

P2860

Q34400398-01A3F836-05BC-4727-A33F-2C0CC49DDD1F

Q34400398-02E92AD8-5E28-4723-82D1-0DCFCAF40CFD

Q34400398-07265723-6CB5-4B9D-9DD4-29312778CE5F

Q34400398-106F7F9C-07B8-48C3-80CD-119E7AEAE376

Q34400398-18218753-5E27-414C-9128-FBFC8134AD27

Q34400398-1AC880CF-C17B-4639-8601-0811A48C4655

Q34400398-1BD53874-681E-4B4C-A126-DAF9F3CD6F8E

Q34400398-203A9700-73D5-4F1F-A98F-93094784D4CC

Q34400398-217A00BD-2EE7-4C21-B304-278BB02BAA43

Q34400398-270AEEA3-C8C3-4E19-86E7-BE4BCCD0739D

P2888

Q34400398-196FD937-DFFB-4C91-BBAD-852FCC459DB0

P304

Q34400398-D2664250-EB1A-4D2B-9014-47C28722ACFA

P31

Q34400398-4E4BD7AB-4298-43DA-845E-CBAA214B7287

P356

Q34400398-20F376B8-C563-465C-A9C1-196BC4F63F54

P407

Q34400398-8EC69E9E-AA77-4CB7-97B9-71D7F93FA124

P433

Q34400398-C9F2B563-4C00-413C-B7C7-A09F65DE4231

P478

Q34400398-84E1A6FA-12DD-44A8-BC9D-096E632DA921

P577

Q34400398-EA60736A-D9E5-4EA3-9D6E-63C020A1A9CB

P5875

Q34400398-7B1E1DCD-5724-4796-BA2C-5C8AAC5F145B

P6179

Q34400398-A6272A05-8C38-4722-9FFF-E916CCC17B50

P698

Q34400398-698C3AFA-740F-427E-8DED-94678D9E87DD

P932

Q34400398-3B567E3F-E8C2-4ECF-A6BF-AC338BEAB966

P356

P1433

P1476

MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy

@en

P2093

A S Azmi

http://www.w3.org/2001/XMLSchema#string

D Yang

http://www.w3.org/2001/XMLSchema#string

F H Sarkar

http://www.w3.org/2001/XMLSchema#string

F W J Beck

http://www.w3.org/2001/XMLSchema#string

P A Philip

http://www.w3.org/2001/XMLSchema#string

R M Mohammad

http://www.w3.org/2001/XMLSchema#string

S Banerjee

http://www.w3.org/2001/XMLSchema#string

S Wang

http://www.w3.org/2001/XMLSchema#string

Z Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy

Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation

Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations

Regulation of p53 stability by Mdm2

p53, the cellular gatekeeper for growth and division

Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation

Metal ions as regulators of the conformation and function of the tumour suppressor protein p53: implications for carcinogenesis.

MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function

Structural biology of zinc.

P2888

P304

117-126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2010.403

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

238041072

http://www.w3.org/2001/XMLSchema#string

P6179

1008725782

http://www.w3.org/2001/XMLSchema#string

P698

20818437

http://www.w3.org/2001/XMLSchema#string

P932

3000878

http://www.w3.org/2001/XMLSchema#string